The mission of the Biomarker Analysis Laboratory is to develop and validate biomarkers in order to continually improve cancer patient's treatment and care. The development and validation of biomarkers can be used for the early detection of cancer, as well as the selection of patients to specific therapies in order to improve treatment outcomes.
The biomarker Analysis Laboratory is particularly focused on development and validation of biomarkers in lung cancer, both in non-small cell (NSCLC) and small cell lung cancer (SCLC).
The research interests are:
Biomarkers for Early Detection of Lung Cancer: A particular focus of the laboratory is the study of micro RNA (miRNA) and messenger RNA (mRNA) profiling of bronchial preneoplasia in order to identify new markers for early detection as well as new targets for chemoprevention and treatment of lung cancer.
Study Lead: Celine Mascaux, M.D., Ph.D.
Predictive markers for new targeted therapies: The laboratory is focusing particularly on the following pathways:
EGFR Biomarkers: Study Lead: Fred R. Hirsch, M.D., Ph.D.
IGF1R Biomarkers: Study Lead: Murry Wynes, Ph.D.
ALK – EML4 Fusion: Study Lead: Fred R. Hirsch, M.D., Ph.D.
Folate Receptor related biomarkers: Study Lead: Daniel Christoph, M.D., Ph.D.
MET Biomarker: Study Lead: Fred R. Hirsch, M.D., Ph.D. Murry Wynes, Ph.D.
FGFR1 Biomarker: Study Lead: Fred R. Hirsch, M.D., Ph.D. Murry Wynes, Ph.D.
Epithilial Mesenchymal Transitions: Study Leads: Fred R. Hirsch, M.D., Ph.D. and Samir Witta, M.D., Ph.D.
SWOG collaboration: Dr. Fred R. Hirsch is a co-chair of Southwest Oncology Group (SWOG) Lung Cancer Correlative Science Committee and part of the SWOG Lung Committee Leadership. The laboratory is performing many correlative biomarker studies related to SWOG’s clinical trials.
Industry collaboration: The lab is collaborating in several clinical trials with specific biomarker studies.